Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial

Mašić, Dženan; Stengaard‐Pedersen, Kristian; Løgstrup, Brian Bridal; Hørslev‐Petersen, Kim; Hetland, Merete Lund; Junker, Peter; Østergaard, Mikkel; Ammitzbøll, Christian Gytz; Möller, Sören; Christensen, Robin; Ellingsen, Torkell

doi:10.1007/s00296-020-04756-5

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it is of great importance whether drugs used to treat RA can have a negative effect on metabolism, which, in turn, may be a prerequisite for the development of other diseases associated with metabolic disorders. Thus, in a clinical study [ 63 ], it was found that treatment of patients with RA with a combination of adalimumab and methotrexate or methotrexate alone led to a significant increase in cholesterol levels. It is also important to study the changes in the microbiome in RA and its treatment since metabolism also depends on the qualitative and quantitative composition of intestinal bacteria.…”

Section: Discussionmentioning

confidence: 99%

Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a progressive autoimmune disease that affects the joints. It has been proven that, with the development of RA, there are changes in the metabolism of cells located in the focus of inflammation. In this article, we describe the connection between metabolism and inflammation in the context of rheumatoid arthritis. We consider in detail the changes in metabolic processes and their subsequent immunomodulatory effects. In particular, we consider how changes in mitochondrial functioning lead to the modulation of metabolism in rheumatoid arthritis. We also describe the main features of the metabolism in cells present in the synovial membrane during inflammation, and we discuss possible targets for the therapy of rheumatoid arthritis.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…153 In a secondary analysis of the Optimised Treatment Algorithm for Patients With Early Rheumatoid Arthritis (OPERA) trial, comparing the effects of adalimumab and methotrexate ( n = 86) versus methotrexate and placebo ( n = 88), there was no significant between-group difference in the changes at 1 year versus baseline in total, LDL cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride concentrations. 154 In an observational study of 262 patients with psoriasis, 12-week treatment with methotrexate significantly reduced total cholesterol ( p < 0.05), LDL cholesterol ( p < 0.05), apolipoprotein B ( p < 0.001) and lipoprotein A ( p < 0.001) in annexin A6, a protein that regulates cholesterol homeostasis, 155 TC and CC genotype carriers of rs11960458 and apolipoprotein B ( p = 0.04) in TT genotype carriers. However, methotrexate also significantly reduced the concentrations of the atheroprotective subfractions, HDL cholesterol ( p = 0.007) and apolipoprotein A1 ( p = 0.04) in TC genotype carriers of rs11960458 .…”

Section: Effects Of Methotrexate On Traditional Cardiovascular Risk F...mentioning

confidence: 99%

Methotrexate and cardiovascular prevention: an appraisal of the current evidence

Mangoni,

Sotgia,

Zinellu

et al. 2023

Therapeutic Advances in Cardiovascular Disease

View full text Add to dashboard Cite

New evidence continues to accumulate regarding a significant association between excessive inflammation and dysregulated immunity (local and systemic) and the risk of cardiovascular events in different patient cohorts. Whilst research has sought to identify novel atheroprotective therapies targeting inflammation and immunity, several marketed drugs for rheumatological conditions may serve a similar purpose. One such drug, methotrexate, has been used since 1948 for treating cancer and, more recently, for a wide range of dysimmune conditions. Over the last 30 years, epidemiological and experimental studies have shown that methotrexate is independently associated with a reduced risk of cardiovascular disease, particularly in rheumatological patients, and exerts several beneficial effects on vascular homeostasis and blood pressure control. This review article discusses the current challenges with managing cardiovascular risk and the new frontiers offered by drug discovery and drug repurposing targeting inflammation and immunity with a focus on methotrexate. Specifically, the article critically appraises the results of observational, cross-sectional and intervention studies investigating the effects of methotrexate on overall cardiovascular risk and individual risk factors. It also discusses the putative molecular mechanisms underpinning the atheroprotective effects of methotrexate and the practical advantages of using methotrexate in cardiovascular prevention, and highlights future research directions in this area.

show abstract

“…Seidman and Limaiem [1] claim that "synovial fluid aspiration and analysis is a necessary therapeutic and diagnostic procedure useful in alleviating pain from a joint effusion and in the diagnosis of potentially serious joint pathologies. " Moreover, it was found that patients suffering from rheumatoid arthritis (RA) can be at increased risk of cardiovascular disease and mortality when compared to the general population [2].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2022

Arch Orthop

View full text Add to dashboard Cite

Background: Rheumatic diseases are one of the most common problems in modern societies. The majority of rheumatic diseases occur when the human immune system attacks its own tissues, including the joints. Therefore, the aim of this study was to investigate the effect of sex, age, and drugs on element levels in synovial fluids originating from patients with arthritis and rheumatic diseases.Methods: This study was based on a flame atomic absorption (FAAS) and emission spectroscopic analysis (AES) of the concentration of selected essential elements, including both microelements (iron, zinc, copper, and manganese) and macro elements (calcium, magnesium, sodium, and potassium) and their interpretation by statistical methods. Results:The concentrations of essential elements in synovial fluids showed the following order: Mn > Fe > Zn > Cu for microelements, and Na > Mg > Ca > K for macro elements. It was also revealed that in the case of arthritis (rheumatic disease) several elements, such as Fe, Zn, K, Mg, and Ca were accumulated in the synovial fluid. The linear correlation coefficients indicated statistically significant relationships among elements in the investigated samples, such as Fe and Zn, and Ca and Mg. A negative correlation was found between Zn and Na. Conclusions:The chemical profiling of synovial fluids of patients with rheumatic diseases based on the identification of essential elements and applying principal component analysis (PCA), allowed us to identify that the levels of Fe, Zn, Ca, Mg, and K have the highest impact on the differentiation of synovial fluid samples. No significant differences in element levels by sex or age were observed. The drug effect was especially significant for Zn, Cu, Na, and K, where differences in these element levels were noticed.

show abstract

Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial

Cited by 5 publications

References 19 publications

Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis

Effects of Metabolic Disorders in Immune Cells and Synoviocytes on the Development of Rheumatoid Arthritis

Methotrexate and cardiovascular prevention: an appraisal of the current evidence

Untitled

Contact Info

Product

Resources

About